BACKGROUND: Disease-specific instruments, commonly incorporated into clinical trials, provide comprehensive insights into the quality-of-life of patients experiencing that disease. However it is not possible to directly elicit preference-based valuations from such instruments for use in cost-utility analysis. OBJECTIVES: To provide a mapping algorithm for estimating EQ-5D index scores from the Urinary Incontinence-specific Quality of Life Questionnaire (I-QOL) based on nationally representative samples of patients with idiopathic or neurogenic overactive bladder (OAB) syndrome using EQ-5D preference valuations based on both the UK and US general populations. METHODS: Analyses were conducted for 2505 patients from the Adelphi OAB Disease Specific Programme, a cross-sectional study of patients consulting with idiopathic or neurogenic OAB, undertaken in the USA and Europe in 2010. A range of statistical mapping techniques including OLS, CLAD, Tobit, GLMs, reverse GLMs and reverse two-part GLMs were used. Ten-fold cross validation techniques were employed to calculate Mean Absolute Error (MAE) and Root Mean Squared Error (RMSE) goodness of fit statistics. Various predictor lists together with a method combining stepwise selection with multivariable fractional polynomial techniques to allow non-linear relationships to feature were pursued. RESULTS: Choice of predictors was consistent for both the UK and USA EQ-5D tariffs. For idiopathic, the best model included IQOL Composite Score and age (both modelled non-linearly). For neurogenic the best model was I-QOL Social Embarrassment Score modelled linearly only. Best fit results were better in the idiopathic (nϭ2351: MAE ϭ 0.10. RMSE ϭ 0.14) than neurogenic sample (nϭ254: MAE ϭ 0.17. RMSE ϭ 0.22). CONCLUSIONS: This research provides algorithms for mapping EQ-5D index scores from I-QOL allowing calculation of appropriate preferencebased health-related quality-of-life scores for use in cost-effectiveness analyses when only I-QOL data are available. The strongest results were for idiopathic patients, but those for neurogenic are consistent with other published mapping studies. OBJECTIVES:In Europe, Health Technology Assessment (HTA) bodies produce coverage decisions that guide public funding of pharmaceuticals. This analysis examines and weights those factors that drive HTA coverage decisions, focusing on the National Institute for Health and Clinical Excellence (NICE) in England and Wales, the Scottish Medicines Consortium (SMC), the Dutch College voor Zorgverzekeringen (CVZ), and the French Haute Autorité de Sante (HAS). METHODS: A dataset of approximately 1000 HTA coverage decisions by NICE, SMC, CVZ and HAS from the period 2004-2009 was created, containing more than 30 clinical, economic, process and socio-economic factors extracted from published HTA reports. A three-cate-A243
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.